|Articles|January 1, 2020

ART Adherence in Transgender and Gender Nonconforming People

Author(s)M. May Zhang

A recent study published in Transgender Health analyzed transgender and gender-nonconforming ART adherence based on the US Trans Survey, the largest survey of TGNC people in the United States.

Transgender and gender nonconforming (TGNC) people are at significantly increased risk for acquiring HIV. In 2015, the number of transgender people diagnosed with HIV was 3 times the national average. Transgender women have 49 times the odds of having HIV compared with the general population, and transgender men also have notably higher rates of infection.

Antiretroviral therapy (ART) decreases morbidity, mortality, and transmission; therefore, ART adherence is critical to the health of TGNC patients with HIV. Understanding adherence patterns is the first step to combatting the HIV epidemic in this population.

A recent study published in Transgender Health analyzed TGNC ART adherence based on the US Trans Survey (USTS), the largest survey of TGNC people in the United States. This large-scale evaluation, which reached TGNC people from many backgrounds, may provide more representative data than previous studies focusing on HIV patients connected to health care.

The researchers studied data from the 2015 USTS, in which 162 respondents reported an HIV diagnosis and ART prescription. Within this group, 66% of respondents were classified as adherent, and 34% were considered nonadherent. The researchers then studied how other factors—including race, living arrangements, sex work history, and substance use—differed in adherent vs. nonadherent populations.

A higher proportion of whites and Hispanics were adherent compared to black individuals. Adherent individuals reported higher rates of home ownership, while nonadherent individuals were more likely to report “other” living conditions, such as roommate situations, and homelessness. Additionally, nonadherent participants reported higher rates of verbal harassment, sex work, and illegal/illicit drug use in the past year, and lower rates of seeing a doctor due to cost in the past year.

These findings support previous data that social determinants of health play a critical role in ART adherence and HIV outcomes. One particularly high-priority population may be black TGNC individuals, who report both higher HIV rates, and lower adherence rates. Vulnerable TGNC populations in unstable sociostructural conditions, such as homelessness, sex work, and drug use, are more prone to nonadherence.

As accessible, approachable health care workers, community pharmacists have both opportunity and responsibility to counsel at-risk patients regarding ART adherence. This may prove to be a critical step to improve health outcomes, and decrease health disparities in this vulnerable population.

This article, Understanding ART Adherence in Transgender People with HIV, originally appeared in Pharmacy Times.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.